We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Gene “Toggle” Regenerates Injured Heart Cells

By LabMedica International staff writers
Posted on 08 May 2012
For the first time, researchers have transformed scar tissue that grows after a heart attack into regenerated heart muscle using microRNAs, according to new lab animal research. More...
If validated in human studies, this finding could help prevent heart failure after a heart attack and applied to other types of tissue regeneration.

The study’s findings were reported online before print April 26, 2012, in Circulation Research, an American Heart Association journal. After a heart attack, heart muscle does not effortlessly regenerate and it accumulates scar tissue, comprised of cells called fibroblasts--increasing risk for heart failure.

“Researchers have tried various approaches, including the use of stem cells, to regenerate damaged heart muscle tissue,” said Victor J. Dzau, MD, the study’s senior author and a professor of medicine at Duke University Medical Center (Durham, NC, USA). “This is the first study to use microRNA, which are small molecules that control gene expression, to reprogram fibroblasts into heart muscle cells. We have not only shown evidence of this tissue regeneration in cell cultures, but also in mice.”

Using microRNA is simpler than many other tissue-regenerating approaches, according to Dr. Dzau, who is also chancellor for health affairs at Duke University. For example, stem cells are not easy to work with and have ethical issues surrounding their use, he noted. “This research represents a major advance in regenerative medicine overcoming the difficulties encountered with stem cells, and may be applied to other conditions of tissue damage such as stroke and spinal cord injury.”

Dr. Dzau’s team identified a combination of three microRNA types that convert fibroblasts to muscle cells. In the next phase of research, the researchers will assess whether microRNAs repair damaged hearts in larger animals and improve heart function. If those studies prove safe and effective, they will begin human studies. “If everything comes to fruition, I think we will see this as a therapy in the next decade,” Dr. Dzau said. “Conceivably, we’ll use it to regenerate hearts damaged by heart attacks, avoiding heart failure and saving lives.”

Related Links:

Duke University Medical Center




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.